Analysis of Vancomycin market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
The global vancomycin market is projected to increase from a valuation of US$ 313.7 Mn in 2020 to US$ 465.1 Mn by the end of 2027. Demand for vancomycin to expand at a CAGR of 5.8% during the forecast period.
Vancomycin Market Size (2020)
US$ 313.7 Mn
Projected Year Value (2027)
US$ 465.1 Mn
Global Market Growth Rate (2021-2027)
China Market Growth Rate (2021-2027)
Key Companies Profiled
Demand for linezolid is set to increase at the highest CAGR over the forecast period with a broad spectrum of activity against many gram-positive bacteria.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
“Rising Prevalence of Infectious Diseases to Stimulate Industry Growth”
The global market for vancomycin was valued at US$ 313.7 Mn in 2020.
Vancomycin is a glycopeptide antibiotic that is used to treat certain infections caused by methicillin-resistant Staphylococcus aureus, such as skin infections, sepsis, endocarditis, bone & joint infections, and meningitis. Inflammatory medicines are usually administered as a first-line treatment, with doses adjusted according to the patient's blood concentration.
Blood levels can be examined to determine the correct dose. When taken through the parenteral route, it is also suggested as a treatment for severe clostridium difficile colitis. When taken by mouth, it is poorly absorbed. Adverse effects such as injection site pain and allergic reactions are prevalent. It's also probably safe to use when breastfeeding. It's a glycopeptide antibiotic that works by inhibiting cell walls from forming.
Vancomycin demand is predicted to grow due to rising prevalence of infectious diseases, increased awareness programs, and government financing for the research and development of new treatments. The market is predicted to expand at a 5.8% CAGR from 2021 to 2027.
“Positive Mechanism of Vancomycin & Rising Investments in R&D Activities to Foster Market Expansion”
The bactericidal activity of vancomycin is mostly due to its reduction of cell-wall formation. It prevents N-acetylmuramic acid and N-acetylglucosamine peptide subunits from being incorporated into the peptidoglycan matrix, the most critical structural component of Gram-positive cell walls.
Vancomycin forms hydrogen bonds with D-alanyl-D-alanine moieties at the end of the peptide, preventing them from being integrated into the peptidoglycan matrix. It also has an impact on bacterial cell membrane permeability and RNA synthesis.
No cross-resistance occurs between vancomycin and other antibiotic medications. Vancomycin does not have any effect on gram-negative bacteria, mycobacteria, or even fungi in vitro.
The global vancomycin industry is growing as antibiotic consumption rises in low- and middle-income nations, with pharmaceutical companies investing heavily in research and development, besides the rising prevalence of infectious diseases.
“Rising Use of Generic Alternatives & Certain Side Effects Hampering Market Value”
Two typical adverse drug reactions associated with IV vancomycin are severe local pain and thrombophlebitis (which affect about 1% of patients). Clinical experiments conducted in the mid-1950s revealed that early impure versions of vancomycin tablets caused kidney damage (nephrotoxicity) and hearing loss (ototoxicity). Nephrotoxicity was discovered to be a rare adverse effect in later investigations using purer forms of vancomycin (0.1% to 1% of patients).
Certain limitations, such as rising use of generic alternatives, particularly as patents expire, and short lifecycle of medications, are expected to hinder vancomycin market growth.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
“Rise in VRSA Infections to Boost Market Revenue in North America”
North America is expected to hold a significant share of the global vancomycin market because of rising vancomycin-resistant Staphylococcus aureus (VRSA) infections, increased R&D initiatives, and rising demand for new treatments.
The developed healthcare sector and increased consumer awareness about various treatments for infectious illnesses are driving market growth in North America.
“Rapid Deployment of Innovative Treatments Driving Market Expansion”
The U.S. vancomycin market was valued at US$ 84.5 Mn in 2020 and is anticipated to rise at the highest CAGR over the forecast period.
The United States is expected to provide lucrative revenue growth possibilities for vancomycin suppliers because of rising consumer healthcare spending and early acceptance of innovative and new treatments.
Existence of prominent manufacturers and advanced healthcare facilities are driving market growth in the U.S. The United States is projected to dominate the market owing to the growing usage of superior technical equipment and well-established healthcare infrastructure.
“Government Initiatives for Infection Control to Fuel Market Growth”
The market in China is projected to reach a valuation of US$ 102.3 Mn by 2027, representing a 9.4% CAGR from 2021 to 2027.
China is expected to occupy a considerable share of the global vancomycin market due to rising population, greater healthcare awareness, and higher demand for early-phase identification.
Growing number of pharmaceutical manufacturers, government help for infection control, and widespread use of generic drugs are driving market expansion in the country.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
“Growing Usage of Linezolid for Infection Prevention”
Linezolid is a drug that is used to treat infections such as pneumonia and skin diseases. Linezolid belongs to the oxazolidinones class of antibacterials. It works by preventing bacteria from growing.
The linezolid segment is projected to occupy a significant share of the global vancomycin market due to growing usage of linezolid and its capacity to treat a variety of gram-positive bacterial infections. Moreover, improved disease diagnostic techniques, as well as increased research on combination medicines, will drive market demand.
“Increasing Consumption of Sepsis Drugs & Treatments Driving Market Demand”
According to the Centers for Disease Control and Prevention (CDC), there are roughly 1.7 million instances of sepsis each year. Furthermore, in the United States, this sort of illness kills nearly 270,000 people each year.
The body's severe response to an infection is known as sepsis. Sepsis occurs when an existing infection sets off a chain reaction throughout the body. Sepsis can quickly progress to tissue damage, organ failure, and death if not treated promptly.
Sepsis drugs and treatments are cost-effective and considered the first line of treatment, making the sepsis application segment the most profitable over the forecast period.
The COVID-19 pandemic triggered an unprecedented global scenario, with healthcare at its core. The pandemic damaged several enterprises' value and supply chains, notably the vancomycin industry.
With rapid spread of the disease, several economies and sectors were disrupted, resulting in a recession as offices, factories, and markets closed. As a result, vancomycin demand and supply were suspended, resulting in a significant drop in the growth of extended-release antibiotics. Furthermore, the number of patients visiting hospitals and clinics decreased, resulting in a fall in treatment rates.
However, advances in medical research and the development of novel therapies and treatments to effectively treat a variety of health-related disorders have resulted in an increase in the demand for novel medications. With the reopening of economies and markets, extended vancomycin demand is projected to recover from the current downturn.
Vancomycin is a competitive and moderately fragmented market. There are many players in the sector under scrutiny, including both, small and large pharmaceutical companies. Furthermore, a wave of early-stage biotech companies has entered the market in response to developing antibiotic resistance.
For instance :
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesBuy Now
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
In 2021, the global vancomycin market stood at a valuation of US$ 331.5 Mn.
The China vancomycin market is anticipated to reach US$ 102.3 Mn by 2027.
Vancomycin sales are expected to reach US$ 465.1 Mn by 2027.
From 2021 to 2027, global consumption of vancomycin is predicted to rise at a CAGR of 5.8%.
Key suppliers of vancomycin are Alvogen, MGB Biopharma Limited, Oragenics, Aphios Corporation, and Microbiotix.
The market in Japan is expected to exhibit 3.1% CAGR, while Japan is set to experience a higher 4.6% CAGR, over the forecast period.
Need An Exclusive Report For Your Unique Requirement?